Which statement accurately describes competitive binding assays?

Which statement accurately describes competitive binding assays?

• A. Excess binding sites for the analyte are provided.
• B. Labeled and unlabeled analyte are present in equal amounts.
• C. The concentration of patient analyte is inversely proportional to bound label.
• D. All the patient analyte is bound in the reaction.

Answer: (C)

Competitive binding assays rely on a limited number of binding sites that must be shared between a labeled version of the analyte and the patient’s unlabeled analyte. The key feature is that the amount of bound labeled tracer becomes smaller as the concentration of patient analyte increases. Why? because more of the available sites are taken by the patient’s analyte, leaving less room for the labeled tracer to bind. That creates an inverse relationship between the patient’s analyte concentration and the signal from bound label, which is exactly what is measured to quantify the analyte. The other statements don’t describe the setup or the readout in the same way. Having excess binding sites would reduce the competition and change the expected signal pattern, so it isn’t the defining scenario of a competitive assay. Requiring equal amounts of labeled and unlabeled analyte isn’t essential to the concept and isn’t the defining feature either. And assuming all patient analyte binds ignores the competitive dynamics—in practice, only a portion binds at equilibrium, with the rest remaining free and the signal reflecting the competition.

Competitive binding assays rely on a limited number of binding sites that must be shared between a labeled version of the analyte and the patient’s unlabeled analyte. The key feature is that the amount of bound labeled tracer becomes smaller as the concentration of patient analyte increases. Why? because more of the available sites are taken by the patient’s analyte, leaving less room for the labeled tracer to bind. That creates an inverse relationship between the patient’s analyte concentration and the signal from bound label, which is exactly what is measured to quantify the analyte.

The other statements don’t describe the setup or the readout in the same way. Having excess binding sites would reduce the competition and change the expected signal pattern, so it isn’t the defining scenario of a competitive assay. Requiring equal amounts of labeled and unlabeled analyte isn’t essential to the concept and isn’t the defining feature either. And assuming all patient analyte binds ignores the competitive dynamics—in practice, only a portion binds at equilibrium, with the rest remaining free and the signal reflecting the competition.